Savient Investor Asks 2nd Circ. To Reopen Fraud Case
Savient, which developed the drug pegloticase to treat gout in sick, treatment-resistant patients, allegedly misled the investing public by failing to quickly disclose that five patients had serious cardiovascular incidents while taking pegloticase in trials.
Savient's eventual disclosure of the news in 2008 caused its...
To view the full article, register now.